SRR_accession	QC_summary	SRX_accession	SRS_accession	SRP_accession	Experiment_title	GEO_series
SRR34562517	PASS	SRX29704696	SRS25814445	SRP601346	GSM9104933: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562518	PASS	SRX29704695	SRS25814444	SRP601346	GSM9104932: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562519	PASS	SRX29704694	SRS25814443	SRP601346	GSM9104931: Cyp2b-null male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562520	PASS	SRX29704693	SRS25814442	SRP601346	GSM9104930: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562521	PASS	SRX29704692	SRS25814441	SRP601346	GSM9104929: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562522	PASS	SRX29704691	SRS25814440	SRP601346	GSM9104928: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562523	PASS	SRX29704690	SRS25814439	SRP601346	GSM9104927: Cyp2b-null male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562524	PASS	SRX29704689	SRS25814438	SRP601346	GSM9104926: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562525	PASS	SRX29704688	SRS25814436	SRP601346	GSM9104925: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562526	PASS	SRX29704687	SRS25814437	SRP601346	GSM9104924: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562527	PASS	SRX29704686	SRS25814434	SRP601346	GSM9104923: Cyp2b-null male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562528	PASS	SRX29704685	SRS25814435	SRP601346	GSM9104922: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562529	PASS	SRX29704684	SRS25814433	SRP601346	GSM9104921: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562530	PASS	SRX29704683	SRS25814432	SRP601346	GSM9104920: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562531	PASS	SRX29704682	SRS25814431	SRP601346	GSM9104919: hCYP2B6-Tg male gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562532	PASS	SRX29704681	SRS25814430	SRP601346	GSM9104918: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562533	PASS	SRX29704680	SRS25814429	SRP601346	GSM9104917: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562534	PASS	SRX29704679	SRS25814428	SRP601346	GSM9104916: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562535	PASS	SRX29704678	SRS25814427	SRP601346	GSM9104915: hCYP2B6-Tg male gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562536	PASS	SRX29704677	SRS25814426	SRP601346	GSM9104914: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 5; Mus musculus; RNA-Seq	GSE302489
SRR34562537	PASS	SRX29704676	SRS25814425	SRP601346	GSM9104913: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562538	PASS	SRX29704675	SRS25814424	SRP601346	GSM9104912: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562539	PASS	SRX29704674	SRS25814422	SRP601346	GSM9104911: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562540	PASS	SRX29704673	SRS25814423	SRP601346	GSM9104910: hCYP2B6-Tg male gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562541	PASS	SRX29704671	SRS25814420	SRP601346	GSM9104908: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562542	PASS	SRX29704670	SRS25814419	SRP601346	GSM9104907: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562543	PASS	SRX29704669	SRS25814418	SRP601346	GSM9104906: Cyp2b-null female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562545	PASS	SRX29704668	SRS25814417	SRP601346	GSM9104905: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562546	PASS	SRX29704667	SRS25814415	SRP601346	GSM9104904: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562547	PASS	SRX29704666	SRS25814416	SRP601346	GSM9104903: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562548	PASS	SRX29704665	SRS25814414	SRP601346	GSM9104902: Cyp2b-null female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562549	PASS	SRX29704663	SRS25814412	SRP601346	GSM9104900: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562550	PASS	SRX29704662	SRS25814411	SRP601346	GSM9104899: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562551	PASS	SRX29704661	SRS25814410	SRP601346	GSM9104898: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562552	PASS	SRX29704664	SRS25814413	SRP601346	GSM9104901: Cyp2b-null female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562553	PASS	SRX29704660	SRS25814409	SRP601346	GSM9104897: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562554	PASS	SRX29704659	SRS25814408	SRP601346	GSM9104896: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562555	PASS	SRX29704658	SRS25814407	SRP601346	GSM9104895: hCYP2B6-Tg female gastrocnemius, 10 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562557	PASS	SRX29704655	SRS25814404	SRP601346	GSM9104892: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562558	PASS	SRX29704654	SRS25814403	SRP601346	GSM9104891: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562559	PASS	SRX29704653	SRS25814402	SRP601346	GSM9104890: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
SRR34562560	PASS	SRX29704656	SRS25814405	SRP601346	GSM9104893: hCYP2B6-Tg female gastrocnemius, 1 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562561	PASS	SRX29704652	SRS25814401	SRP601346	GSM9104889: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 4; Mus musculus; RNA-Seq	GSE302489
SRR34562562	PASS	SRX29704651	SRS25814400	SRP601346	GSM9104888: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 3; Mus musculus; RNA-Seq	GSE302489
SRR34562563	PASS	SRX29704650	SRS25814399	SRP601346	GSM9104887: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 2; Mus musculus; RNA-Seq	GSE302489
SRR34562564	PASS	SRX29704649	SRS25814398	SRP601346	GSM9104886: hCYP2B6-Tg female gastrocnemius, 0 mg/kg/day PFOS treatment for 21 days via oral gavage rep 1; Mus musculus; RNA-Seq	GSE302489
